Article information
Full text is only aviable in PDF
Bibliografía
[1.]
ATS.
Proceedings of the ATS Workshop on Refractory Asthma.
Am J Respir Crit Care Med, 162 (2000), pp. 2341-2351
[2.]
J. Serra-Batlles, V. Plaza, E. Morejón, A. Comella, J. Brugues.
Cost of asthma according to the degree of severity.
Eur Respir J, 12 (1998), pp. 1322-1326
[3.]
Global Initiative for Asthma Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. 2002.
[4.]
D.W. Cockcroft, V.A. Swystun.
Asthma control versus asthma severity.
J Allergy Clin Immunol, 98 (1996), pp. 1016-1018
[5.]
US Department of Health and Human Services. Internacional consensus report of diagnosis and treatment of asthma. Bethesda: National Heart, Lung and Blood Institute; 1992.
[6.]
A. López Viña.
Actitudes para fomentar el cumplimiento terapéutico en el asma.
Arch Bronconeumol, 41 (2005), pp. 334-340
[7.]
A.E. Tattersfield, D.S. Postma, P.J. Barnes, K. Svensson, C.A. Bauer, P.M. O’Byrne, et al.
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET Internacional Study Group.
Am J Respir Crit Care Med, 160 (1999), pp. 594-599
[8.]
A.J. Woolcok, K. Yan, C.M. Salome.
Effect of therapy on bronchial hyperresponsiveness in the long-term management of asthma.
Clin Allergy, 18 (1988), pp. 165-176
[9.]
M.R. Sears, D.R. Taylor, C.G. Print, D.C. Lake, Q. Li, E.M. Flannery, et al.
Regular inhaled beta-agonist treatment in bronchial asthma.
Lancet, 336 (1990), pp. 1391-1396
[10.]
P.S. Thomas, D.M. Geddes, P.J. Barnes.
Pseudo-steroid resistant asthma.
Thorax, 54 (1999), pp. 352-356
[12.]
D.S. Robinson, D.A. Campbell, S.R. Durham, J. Pfeffer, P.J. Barnes, K.F. Chung.
Systematic assessment of difficult-to-treat asthma.
Eur Respir J, 22 (2003), pp. 478-483
[13.]
L.G. Heaney, E. Conway, C. Kelly, B.T. Johnston, C. English, M. Stevenson, et al.
Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol.
Thorax, 58 (2003), pp. 561-566
[14.]
The ENFUMOSA study group: the ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma.
Eur Respir J, 22 (2003), pp. 470-477
[15.]
I.M. Adcock, C.R. Brown, H. Shirasaki, P.J. Barnes.
Effects of dexamethasone on cytoquine and phorbol ester stimulated c-Fos and c- Jun DNA binding and gene expression in human lung.
Eur Respir J, 7 (1994), pp. 2117-2123
[16.]
A.T. Brinke, A.H. Zwinderman, P.J. Sterk, F. Rabe, E.H. Bel.
“Refractory” eosinophilic airway inflammation in severe asthma.
Am J Respir Crit Care Med, 170 (2004), pp. 601-605
[17.]
I.M. Adcock, D.A. Stevens, P.J. Barnes.
Interactions of glucocorticoids and beta 2-agonists.
Eur Respir J, 9 (1996), pp. 160-168
[18.]
P. Lange, J. Parner, J. Vestbo, Schnohr, J.A. Jensen.
A 15-year follow up study of ventilatory function in adults with asthma.
N Engl J Med, 339 (1998), pp. 310-312
[19.]
F. Paganin, E. Seneterre, J.P. Chanez P Daures, J.M. Cruel, F.B. Michel, et al.
Computed tomography of the lungs in asthma: influence of disease severity and etiology.
Am J Respir Crit Care Med, 153 (1996), pp. 110-114
[20.]
G.E. Silva, D.L. Sherrill, S. Guerra, R.A. Barbee.
Asthma as a risk factor for COPD in a longitudinal study.
Chest, 126 (2004), pp. 59-65
[21.]
N. Jarjour, K. McGill, W.W. Busse, E. Gelfand.
Alternative anti-inflammatory and immunomodulatory therapy.
Lung biology in health and disease. Vol. 86. Severe asthma: pathogenesis and clinical management, pp. 333-339
[22.]
S. Holgate, R. Djukanovic, T. Casale, J. Bousquet.
Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Clin Exp Allergy, 35 (2005), pp. 408-416
[24.]
J.M. Vonk, D.S. Postma, H.N. Boezen, M.H. Grol, J.P. Schouten, G.H. Koeter, et al.
Childhood factors associated with asthma remission after 30 year follow up.
Thorax, 59 (2004), pp. 925-929
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica
